Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells.

Modern medicine is currently undergoing a paradigm shift from conventional disease treatments based on the diagnosis of a generalized disease state to a more personalized, customized treatment model based on molecular-level diagnosis. This uses novel biosensors that can precisely extract disease-related information from complex biological systems. Moreover, with the recent progress in chemical biology, materials science, and synthetic biology, it has become possible to simultaneously conduct diagnosis and targeted therapy (theranostics/theragnosis) by directly connecting the readout of a biosensor to a therapeutic output. These advances pave the way for more advanced and better personalized treatment for intractable diseases with fewer side effects. In this review, we describe recent advances in the development of cutting-edge theranostic agents that contain both diagnostic and therapeutic functions in a single integrated system. By comparing the advantages and disadvantages of each modality, we discuss the future challenges and prospects of developing ideal theranostic agents for the next generation of personalized medicine.

[1]  Jeremy P. Sauer,et al.  Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticles , 2014, Nature Medicine.

[2]  Donghong Zhao,et al.  Neural Stem Cell-Mediated Intratumoral Delivery of Gold Nanorods Improves Photothermal Therapy , 2014, ACS nano.

[3]  Zhe Wang,et al.  Biodegradable gold nanovesicles with an ultrastrong plasmonic coupling effect for photoacoustic imaging and photothermal therapy. , 2013, Angewandte Chemie.

[4]  Jianghong Rao,et al.  Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. , 2014, Small.

[5]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[6]  David L Porter,et al.  Chimeric antigen receptor therapy for cancer. , 2014, Annual review of medicine.

[7]  Yeonkyung Lee,et al.  New paradigm for tumor theranostic methodology using bacteria-based microrobot , 2013, Scientific Reports.

[8]  Funda Meric-Bernstam,et al.  Overcoming implementation challenges of personalized cancer therapy , 2012, Nature Reviews Clinical Oncology.

[9]  Paola Nicolussi,et al.  Functionalized multiwalled carbon nanotubes as ultrasound contrast agents , 2012, Proceedings of the National Academy of Sciences.

[10]  Vladimir P Torchilin,et al.  On-demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles , 2014, Nature Medicine.

[11]  Ralph Weissleder,et al.  A macrophage-targeted theranostic nanoparticle for biomedical applications. , 2006, Small.

[12]  Simon R. Cherry,et al.  A Smart and Versatile Theranostic Nanomedicine Platform based on Nanoporphyrin , 2014, Nature Communications.

[13]  Raymond A. Firestone,et al.  Lessons from 54 years of pharmaceutical research , 2011, Nature Reviews Drug Discovery.

[14]  Raphael Sandaltzopoulos,et al.  Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo , 2013, Cancer Immunology Research.

[15]  Sonke Svenson,et al.  Theranostics: are we there yet? , 2013, Molecular pharmaceutics.

[16]  Martin Fussenegger,et al.  A synthetic multifunctional mammalian pH sensor and CO2 transgene-control device. , 2014, Molecular cell.

[17]  Jibin Song,et al.  Self-assembled plasmonic vesicles of SERS-encoded amphiphilic gold nanoparticles for cancer cell targeting and traceable intracellular drug delivery. , 2012, Journal of the American Chemical Society.

[18]  Shoji Takeuchi,et al.  Metre-long cell-laden microfibres exhibit tissue morphologies and functions. , 2013, Nature materials.

[19]  Martin Fussenegger,et al.  Reward-based hypertension control by a synthetic brain–dopamine interface , 2013, Proceedings of the National Academy of Sciences.

[20]  Tayyaba Hasan,et al.  Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates , 2014, Proceedings of the National Academy of Sciences.

[21]  He Tian,et al.  In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug. , 2014, Journal of the American Chemical Society.

[22]  Peter L. Choyke,et al.  Rapid Cancer Detection by Topically Spraying a γ-Glutamyltranspeptidase–Activated Fluorescent Probe , 2011, Science Translational Medicine.

[23]  R. Shah,et al.  Personalized medicine: is it a pharmacogenetic mirage? , 2012, British journal of clinical pharmacology.

[24]  Theresa M Reineke,et al.  Theranostics: combining imaging and therapy. , 2011, Bioconjugate chemistry.

[25]  Markus Wieland,et al.  Programmable single-cell mammalian biocomputers , 2012, Nature.

[26]  Huangxian Ju,et al.  A multifunctional nanomicelle for real-time targeted imaging and precise near-infrared cancer therapy. , 2014, Angewandte Chemie.

[27]  C. Lagenaur,et al.  Role of CD47 as a marker of self on red blood cells. , 2000, Science.

[28]  Martin Fussenegger,et al.  Self-sufficient control of urate homeostasis in mice by a synthetic circuit , 2010, Nature Biotechnology.

[29]  Jonathan S. Dordick,et al.  Radio-Wave Heating of Iron Oxide Nanoparticles Can Regulate Plasma Glucose in Mice , 2012, Science.

[30]  A. Romaschin,et al.  Theranostics in the growing field of personalized medicine: an analytical chemistry perspective. , 2014, Analytical chemistry.

[31]  Huangxian Ju,et al.  Cell-specific and pH-activatable rubyrin-loaded nanoparticles for highly selective near-infrared photodynamic therapy against cancer. , 2013, Journal of the American Chemical Society.

[32]  Roberto Cattaneo,et al.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded , 2008, Nature Reviews Microbiology.

[33]  Yuebing Zheng,et al.  Towards rational design of multifunctional theranostic nanoparticles: what barriers do we need to overcome? , 2014, Nanomedicine.

[34]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[35]  D. Kirn,et al.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer , 2009, Nature Reviews Cancer.

[36]  Zahi A. Fayad,et al.  Perspectives and opportunities for nanomedicine in the management of atherosclerosis , 2011, Nature Reviews Drug Discovery.

[37]  Yasuteru Urano,et al.  In vivo imaging of intraperitoneally disseminated tumors in model mice by using activatable fluorescent small-molecular probes for activity of cathepsins. , 2014, Bioconjugate chemistry.

[38]  Hisataka Kobayashi,et al.  Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules , 2011, Nature Medicine.

[39]  Martin Fussenegger,et al.  Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome , 2012, Proceedings of the National Academy of Sciences.

[40]  T. Maheswaran,et al.  Theranostics: A treasured tailor for tomorrow , 2014, Journal of pharmacy & bioallied sciences.

[41]  Rex A. Moats,et al.  Neural Stem Cell–Mediated Enzyme/Prodrug Therapy for Glioma: Preclinical Studies , 2013, Science Translational Medicine.

[42]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[43]  Youngmi Kim,et al.  ROS-Responsive Activatable Photosensitizing Agent for Imaging and Photodynamic Therapy of Activated Macrophages , 2013, Theranostics.

[44]  Benjamin Rhau,et al.  Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal , 2014, Proceedings of the National Academy of Sciences.

[45]  Martin Fussenegger,et al.  Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant , 2014, Nature Communications.

[46]  M. Fussenegger,et al.  A Synthetic Optogenetic Transcription Device Enhances Blood-Glucose Homeostasis in Mice , 2011, Science.

[47]  Karen L Wooley,et al.  Hierarchically assembled theranostic nanostructures for siRNA delivery and imaging applications. , 2012, Journal of the American Chemical Society.

[48]  Xiaoqi Sun,et al.  Multifunctional Theranostic Red Blood Cells For Magnetic‐Field‐Enhanced in vivo Combination Therapy of Cancer , 2014, Advanced materials.

[49]  Pui-Chi Lo,et al.  A glutathione-activated phthalocyanine-based photosensitizer for photodynamic therapy. , 2014, Chemistry.

[50]  Ralph Weissleder,et al.  A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. , 2010, Small.

[51]  Masayuki Miura,et al.  Selective ablation of β-galactosidase-expressing cells with a rationally designed activatable photosensitizer. , 2014, Angewandte Chemie.

[52]  Jae Hong Lee,et al.  Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug. , 2013, Journal of the American Chemical Society.

[53]  Wendell A. Lim,et al.  Bacterial Virulence Proteins as Tools to Rewire Kinase Pathways in Yeast and Immune Cells , 2012, Nature.

[54]  Martin Fussenegger,et al.  A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice , 2013, Nature Communications.

[55]  Aaron Fenster,et al.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans , 2011, Nature.

[56]  G. Dai,et al.  A Theranostic Small Interfering RNA Nanoprobe Protects Pancreatic Islet Grafts From Adoptively Transferred Immune Rejection , 2012, Diabetes.

[57]  Keith M. Stantz,et al.  Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse , 2012, Cancer Nanotechnology.

[58]  K. Hong,et al.  Folate-based near-infrared fluorescent theranostic gemcitabine delivery. , 2013, Journal of the American Chemical Society.

[59]  Christina D Smolke,et al.  Reprogramming Cellular Behavior with RNA Controllers Responsive to Endogenous Proteins , 2010, Science.

[60]  Kwan Soo Hong,et al.  An activatable theranostic for targeted cancer therapy and imaging. , 2014, Angewandte Chemie.

[61]  D. Irvine,et al.  Bio-inspired, bioengineered and biomimetic drug delivery carriers , 2011, Nature Reviews Drug Discovery.

[62]  N. Forbes.  Engineering the perfect (bacterial) cancer therapy , 2010, Nature Reviews Cancer.

[63]  R. Weiss,et al.  Cancer Cells Multi-Input RNAi-Based Logic Circuit for Identification of Specific , 2011 .

[64]  Ben Zhong Tang,et al.  Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. , 2014, Journal of the American Chemical Society.

[65]  Jennifer Sturgis,et al.  A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. , 2007, Nano letters.

[66]  Takafumi Miyamoto,et al.  Synthesizing biomolecule-based Boolean logic gates. , 2013, ACS synthetic biology.